BACKGROUND: Detection of hepatitis C virus (HCV) reinfection and intercalation (ie, intermittent recurrent bouts of viremia with homologous virus interspersed with aviremic periods) requires extensive and frequent evaluation and viral sequencing. METHODS: HCV infection outcomes were studied prospectively in active injection drug users with recurrent HCV RNA-positive tests after serial negative results. HCV viremia and viral sequences (Core/E1) were assessed from monthly blood samples. RESULTS: Viral clearance, reinfection, and intercalating infection were all detected. Among 44 participants with apparently resolved HCV (26 incident HCV clearers and 18 enrolled with already resolved infection), 36 (82%) remained persistently HCV RNA negative, but 8 demonstrated intermittent recurrent viremia. Four of these (50%) had confirmed reinfection with a heterologous virus; 3 demonstrated viral intercalation, and 1 was not classifiable as either. Estimated incidence of first reinfection was 5.4 per 100 person-years (95% confidence interval, 2.0-14.5). Six (75%) participants, including 3 of 4 with reinfection, demonstrated sustained viral clearance for a median of 26 months since last HCV RNA test. CONCLUSIONS: These results show that frequent monitoring and viral sequencing are required to correctly assess HCV outcomes and estimate incidence of reinfection (which was previously overestimated). Sustained clearance may take many months and occur after episodes of reinfection and viral intercalation. Three of 4 subjects who had confirmed reinfection showed evidence of long-term clearance. Viral intercalation occurs with significant frequency. Further studies of these events, especially immunological, are needed to inform HCV clinical care and vaccine development.
BACKGROUND: Detection of hepatitis C virus (HCV) reinfection and intercalation (ie, intermittent recurrent bouts of viremia with homologous virus interspersed with aviremic periods) requires extensive and frequent evaluation and viral sequencing. METHODS:HCVinfection outcomes were studied prospectively in active injection drug users with recurrent HCV RNA-positive tests after serial negative results. HCV viremia and viral sequences (Core/E1) were assessed from monthly blood samples. RESULTS: Viral clearance, reinfection, and intercalating infection were all detected. Among 44 participants with apparently resolved HCV (26 incident HCV clearers and 18 enrolled with already resolved infection), 36 (82%) remained persistently HCV RNA negative, but 8 demonstrated intermittent recurrent viremia. Four of these (50%) had confirmed reinfection with a heterologous virus; 3 demonstrated viral intercalation, and 1 was not classifiable as either. Estimated incidence of first reinfection was 5.4 per 100 person-years (95% confidence interval, 2.0-14.5). Six (75%) participants, including 3 of 4 with reinfection, demonstrated sustained viral clearance for a median of 26 months since last HCV RNA test. CONCLUSIONS: These results show that frequent monitoring and viral sequencing are required to correctly assess HCV outcomes and estimate incidence of reinfection (which was previously overestimated). Sustained clearance may take many months and occur after episodes of reinfection and viral intercalation. Three of 4 subjects who had confirmed reinfection showed evidence of long-term clearance. Viral intercalation occurs with significant frequency. Further studies of these events, especially immunological, are needed to inform HCV clinical care and vaccine development.
Authors: Chyang T Fang; Leslie H Tobler; Carmen Haesche; Michael P Busch; Bruce Phelps; German Leparc Journal: Transfusion Date: 2003-04 Impact factor: 3.157
Authors: T Santantonio; E Sinisi; A Guastadisegni; C Casalino; M Mazzola; A Gentile; G Leandro; G Pastore Journal: Dig Liver Dis Date: 2003-02 Impact factor: 4.088
Authors: Alberto Larghi; Massimo Zuin; Andrea Crosignani; Maria Lisa Ribero; Cristina Pipia; Pier Maria Battezzati; Giorgio Binelli; Francesco Donato; Alessandro Remo Zanetti; Mauro Podda; Alessandro Tagger Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Thijs J W van de Laar; Richard Molenkamp; Charlotte van den Berg; Janke Schinkel; Marcel G H M Beld; Maria Prins; Roel A Coutinho; Sylvia M Bruisten Journal: J Hepatol Date: 2009-06-18 Impact factor: 25.083
Authors: Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard Journal: J Infect Dis Date: 2015-04-15 Impact factor: 5.226
Authors: Damien C Tully; Judith A Hahn; David J Bean; Jennifer L Evans; Meghan D Morris; Kimberly Page; Todd M Allen Journal: Clin Infect Dis Date: 2022-03-23 Impact factor: 20.999
Authors: Rachel Sacks-Davis; Emma McBryde; Jason Grebely; Margaret Hellard; Peter Vickerman Journal: J R Soc Interface Date: 2015-03-06 Impact factor: 4.118
Authors: Desarae Echevarria; Alexander Gutfraind; Basmattee Boodram; Marian Major; Sara Del Valle; Scott J Cotler; Harel Dahari Journal: PLoS One Date: 2015-08-21 Impact factor: 3.240
Authors: Rachel Sacks-Davis; Campbell K Aitken; Peter Higgs; Tim Spelman; Alisa E Pedrana; Scott Bowden; Mandvi Bharadwaj; Usha K Nivarthi; Vijayaprakash Suppiah; Jacob George; Jason Grebely; Heidi E Drummer; Margaret Hellard Journal: PLoS One Date: 2013-11-07 Impact factor: 3.240
Authors: David A Rolls; Rachel Sacks-Davis; Rebecca Jenkinson; Emma McBryde; Philippa Pattison; Garry Robins; Margaret Hellard Journal: PLoS One Date: 2013-11-01 Impact factor: 3.240